Lynn Kirkpatrick, PhD, CEO, Ensysce Biosciences, Discusses the Recent Breakthrough Therapy Designation for PF614-MPAR

In an interview with Pharm Exec associate editor Don Tracy, Lynn Kirkpatrick, PhD, CEO, Ensysce Biosciences, discusses the FDA’s Breakthrough Therapy Designation for PF614-MPAR, which focuses on protecting patients from drug overdoses.